Study of Convergent Ablation with LARIAT Procedure Versus Standard Catheter Ablation for Persistent Atrial Fibrillation

What this Trial Is About

This clinical trial is designed to evaluate the effectiveness of convergent ablation combined with the LARIAT procedure compared to the standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation AF. Atrial fibrillation is a common heart rhythm disorder that can lead to serious health problems like strokes and heart failure. The study aims to improve treatment outcomes for persistent AF, where current catheter ablation success rates are moderate and can result in further arrhythmias. Participants will be randomly assigned to one of two groups. One group undergoes a two-stage minimally invasive convergent procedure the first stage involves surgical ablation of the left atriums posterior wall plus isolation of the left atrial appendage using the LARIAT device the second stage involves endocardial catheter ablation to complete lesion formation. The other group will receive the standard endocardial catheter ablation alone. The study will monitor safety, recruitment feasibility, and efficacy of these procedures. Throughout the trial, participants will be assessed for recruitment progress, complications within 30 days after procedures, and success in remaining free from atrial arrhythmias over 12 months following a 3-month recovery period. Additional evaluations include symptom improvement, changes in heart function, and heart failure classification. The total study duration extends through 2026, with ongoing monitoring of patients heart rhythm, symptoms, and adverse events.

Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation